Ronald B Postuma1, Jean-Francois Gagnon1, Josie-Anne Bertrand1, Daphné Génier Marchand1, Jacques Y Montplaisir2. 1. From the Department of Neurology (R.B.P.), McGill University, Montreal General Hospital; Centre d'Études Avancées en Médecine du Sommeil (R.B.P., J.-F.G., J.-A.B., D.G.M., J.Y.M.), Hôpital du Sacré-Cœur de Montréal; Department of Psychology (J.-F.G.), Université du Québec à Montréal; and Department of Psychiatry (J.Y.M.), Université de Montréal, Canada. 2. From the Department of Neurology (R.B.P.), McGill University, Montreal General Hospital; Centre d'Études Avancées en Médecine du Sommeil (R.B.P., J.-F.G., J.-A.B., D.G.M., J.Y.M.), Hôpital du Sacré-Cœur de Montréal; Department of Psychology (J.-F.G.), Université du Québec à Montréal; and Department of Psychiatry (J.Y.M.), Université de Montréal, Canada. jy.montplaisir@umontreal.ca.
Abstract
OBJECTIVE: To precisely delineate clinical risk factors for conversion from idiopathic REM sleep behavior disorder (RBD) to Parkinson disease, dementia with Lewy bodies, and multiple system atrophy, in order to enable practical planning and stratification of neuroprotective trials against neurodegenerative synucleinopathy. METHODS: In a 10-year prospective cohort, we tested prodromal Parkinson disease markers in 89 patients with idiopathic RBD. With Kaplan-Meier analysis, we calculated risk of neurodegenerative synucleinopathy, and using Cox proportional hazards, tested the ability of prodromal markers to identify patients at higher disease risk. By combining predictive markers, we then designed stratification strategies to optimally select patients for definitive neuroprotective trials. RESULTS: The risk of defined neurodegenerative synucleinopathy was high: 30% developed disease at 3 years, rising to 66% at 7.5 years. Advanced age (hazard ratio [HR] = 1.07), olfactory loss (HR = 2.8), abnormal color vision (HR = 3.1), subtle motor dysfunction (HR = 3.9), and nonuse of antidepressants (HR = 3.5) identified higher risk of disease conversion. However, mild cognitive impairment (HR = 1.8), depression (HR = 0.63), Parkinson personality, treatment with clonazepam (HR = 1.3) or melatonin (HR = 0.55), autonomic markers, and sex (HR = 1.37) did not clearly predict clinical neurodegeneration. Stratification with prodromal markers increased risk of neurodegenerative disease conversion by 200%, and combining markers allowed sample size reduction in neuroprotective trials by >40%. With a moderately effective agent (HR = 0.5), trials with fewer than 80 subjects per group can demonstrate definitive reductions in neurodegenerative disease. CONCLUSIONS: Using stratification with simply assessed markers, it is now not only possible, but practical to include patients with RBD in neuroprotective trials against Parkinson disease, multiple system atrophy, and dementia with Lewy bodies.
OBJECTIVE: To precisely delineate clinical risk factors for conversion from idiopathic REM sleep behavior disorder (RBD) to Parkinson disease, dementia with Lewy bodies, and multiple system atrophy, in order to enable practical planning and stratification of neuroprotective trials against neurodegenerative synucleinopathy. METHODS: In a 10-year prospective cohort, we tested prodromal Parkinson disease markers in 89 patients with idiopathic RBD. With Kaplan-Meier analysis, we calculated risk of neurodegenerative synucleinopathy, and using Cox proportional hazards, tested the ability of prodromal markers to identify patients at higher disease risk. By combining predictive markers, we then designed stratification strategies to optimally select patients for definitive neuroprotective trials. RESULTS: The risk of defined neurodegenerative synucleinopathy was high: 30% developed disease at 3 years, rising to 66% at 7.5 years. Advanced age (hazard ratio [HR] = 1.07), olfactory loss (HR = 2.8), abnormal color vision (HR = 3.1), subtle motor dysfunction (HR = 3.9), and nonuse of antidepressants (HR = 3.5) identified higher risk of disease conversion. However, mild cognitive impairment (HR = 1.8), depression (HR = 0.63), Parkinson personality, treatment with clonazepam (HR = 1.3) or melatonin (HR = 0.55), autonomic markers, and sex (HR = 1.37) did not clearly predict clinical neurodegeneration. Stratification with prodromal markers increased risk of neurodegenerative disease conversion by 200%, and combining markers allowed sample size reduction in neuroprotective trials by >40%. With a moderately effective agent (HR = 0.5), trials with fewer than 80 subjects per group can demonstrate definitive reductions in neurodegenerative disease. CONCLUSIONS: Using stratification with simply assessed markers, it is now not only possible, but practical to include patients with RBD in neuroprotective trials against Parkinson disease, multiple system atrophy, and dementia with Lewy bodies.
Authors: Jacques Montplaisir; Jean-Francois Gagnon; Maria Livia Fantini; Ronald B Postuma; Yves Dauvilliers; Alex Desautels; Sylvie Rompré; Jean Paquet Journal: Mov Disord Date: 2010-10-15 Impact factor: 10.338
Authors: Alex Iranzo; Francisco Lomeña; Heike Stockner; Francesc Valldeoriola; Isabel Vilaseca; Manel Salamero; Jose Luis Molinuevo; Monica Serradell; Joan Duch; Javier Pavía; Judith Gallego; Klaus Seppi; Birgit Högl; Eduard Tolosa; Werner Poewe; Joan Santamaria Journal: Lancet Neurol Date: 2010-09-16 Impact factor: 44.182
Authors: Christoph Scherfler; Birgit Frauscher; Michael Schocke; Alex Iranzo; Viola Gschliesser; Klaus Seppi; Joan Santamaria; Eduardo Tolosa; Birgit Högl; Werner Poewe Journal: Ann Neurol Date: 2010-12-28 Impact factor: 10.422
Authors: Ronald B Postuma; Jean-François Gagnon; Mélanie Vendette; Catherine Desjardins; Jacques Y Montplaisir Journal: Ann Neurol Date: 2011-01-18 Impact factor: 10.422
Authors: Ronald B Postuma; Paola A Lanfranchi; Helene Blais; Jean-Francois Gagnon; Jacques Y Montplaisir Journal: Mov Disord Date: 2010-10-30 Impact factor: 10.338
Authors: R B Postuma; J F Gagnon; M Vendette; M L Fantini; J Massicotte-Marquez; J Montplaisir Journal: Neurology Date: 2008-12-24 Impact factor: 9.910
Authors: Jean-François Gagnon; Mélanie Vendette; Ronald B Postuma; Catherine Desjardins; Jessica Massicotte-Marquez; Michel Panisset; Jacques Montplaisir Journal: Ann Neurol Date: 2009-07 Impact factor: 10.422
Authors: Stuart J McCarter; David J Sandness; Allison R McCarter; John C Feemster; Luke N Teigen; Paul C Timm; Bradley F Boeve; Michael H Silber; Erik K St Louis Journal: Neurology Date: 2019-08-16 Impact factor: 9.910
Authors: Ronald B Postuma; Alex Iranzo; Birgit Hogl; Isabelle Arnulf; Luigi Ferini-Strambi; Raffaele Manni; Tomoyuki Miyamoto; Wolfgang Oertel; Yves Dauvilliers; Yo-El Ju; Monica Puligheddu; Karel Sonka; Amelie Pelletier; Juan Santamaria; Birgit Frauscher; Smaranda Leu-Semenescu; Marco Zucconi; Michele Terzaghi; Masayuki Miyamoto; Marcus M Unger; Bertrand Carlander; Maria-Livia Fantini; Jacques Y Montplaisir Journal: Ann Neurol Date: 2015-03-13 Impact factor: 10.422
Authors: Jared T Hinkle; Kate Perepezko; Kelly A Mills; Zoltan Mari; Ankur Butala; Ted M Dawson; Alexander Pantelyat; Liana S Rosenthal; Gregory M Pontone Journal: Parkinsonism Relat Disord Date: 2018-08-22 Impact factor: 4.891
Authors: Zachary Kabelac; Christopher G Tarolli; Christopher Snyder; Blake Feldman; Alistair Glidden; Chen-Yu Hsu; Rumen Hristov; E Ray Dorsey; Dina Katabi Journal: Digit Biomark Date: 2019-04-30